SEARCH

SEARCH BY CITATION

References

  • 1
    Muir AJ, Bornstein JD, Killenberg PG; Atlantic Coast Hepatitis Treatment Group. Peginterferon alfa-2b and RBV for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004; 350: 2265-2271.
  • 2
    Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE, Afdhal N, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 131: 470-477.
  • 3
    Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
  • 4
    Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and RBV therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
  • 5
    Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML. IL28B is associated with response to chronic hepatitis C interferon-alpha and RBV therapy. Nat Genet 2009; 41: 1100-1104.
  • 6
    Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
  • 7
    Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al; Swiss Hepatitis C Cohort Study; Swiss HIV Cohort Study. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-1345.
  • 8
    Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in hepatitis C virus-1 patients. Gastroenterology 2010; 139: 120-129.
  • 9
    Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, et al. An interleukin-28B polymorphism determines treatment response of patients with hepatitis C genotypes 2 or 3 who do not achieve a rapid virologic response. Gastroenterology 2010; 139: 821-827.
  • 10
    Herrmann E, Neumann AU, Schmidt JM, Zeuzem S. Hepatitis C virus kinetics. Antivir Ther 2000; 5: 85-90.
  • 11
    Howell CD, Thompson AJ, Ryan K, Zambeeli S, Gorden A, Fried M, et al. IL28 genetic variation associated with early viral kinetics and SVR in HCV genotype 1: The ViraHepC Study. J Hepatol 2010; 52( Suppl. 1): S451.
  • 12
    Neumann AU, Bibert S, Haagmans B, Soulier A, Negro F, Lagging M. IL28B polymorphism is significantly correlated with IFN anti-viral effectiveness already on first day of pegylated interferon-α and ribavirin therapy of chronic HCV infection. J Hepatol 2010; 52( Suppl. 1): S468.
  • 13
    Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 2006; 80: 4501-4509.
  • 14
    Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah M, et al. IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003; 4; 69-77.
  • 15
    Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003; 4: 63-68.
  • 16
    Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, MacDonald MR, et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006; 131: 1887-1898.
  • 17
    Robek MD, Boyd BS, Chisari FV. Lambda interferon inhibits hepatitis B and C virus replication. J Virol 2005; 79: 3851-3854.
  • 18
    Ank N, Iversen MB, Bartholdy C, Staeheli P, Hartmann R, Jensen UB, et al. An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J Immunol 2008; 180: 2474-2485.
  • 19
    Muir AJ, Shiffman ML, Zaman A, Yoffe B, de la Torre A, Flamm S, et al. Phase 1b study of pegylated interferon lambda 1 with or without RBV in patients with chronic genotype 1 hepatitis C virus infection. HEPATOLOGY 2010; 52: 822-832.
  • 20
    Coccia EM, Severa M, Giacomini E, Monneron D, Remoli ME, Julkunen I, et al. Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol 2004; 34: 796-805.
  • 21
    Doyle SE, Schreckhise H, Khuu-Duong K, Henderson K, Rosler R, Storey H, et al. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. HEPATOLOGY 2006; 44: 896-906.
  • 22
    Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, et al; Hokuriku Liver Study Group. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010; 139: 499-509.
  • 23
    Urban TJ, Thompson AJ, Bradrick S, Fellay J, Schuppan D, Cronin KD, et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in chronic hepatitis C patients. HEPATOLOGY 2010; doi:10.1002/hep.23912.
  • 24
    Fellay J, Thompson AJ, Ge D, Gumbs CE, Urban TJ, Shianna KV, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010; 464: 405-408.
  • 25
    LabCorp. LabCorp Service Announcement.http://people.genome.duke.edu/…/L8464-0710-Service-Announcement-FINAL.pdf. Accessed November 5, 2010.
  • 26
    Zineh I, Lesko LJ. Pharmacogenetics in medicine: barriers, critical factors and a framework for dialogue. Per Med 2009; 6: 359-361.
  • 27
    O'Brien TR. Inteferon-alfa, interferon-λ and hepatitis C. Nat Genet 2009; 41: 1048-1050.